Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–drug conjugates: in search of partners of choice
Jesús Fuentes‐Antrás, Sofia Genta, Abi Vijenthira, et al.
Trends in cancer (2023) Vol. 9, Iss. 4, pp. 339-354
Open Access | Times Cited: 118

Showing 26-50 of 118 citing articles:

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2160-2160
Open Access | Times Cited: 19
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
Md Abdus Subhan, Vladimir P. Torchilin
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1242-1242
Open Access | Times Cited: 17
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Perspectives on Nuclear Magnetic Resonance Spectroscopy in Drug Discovery Research
Janet Caceres‐Cortes, Bradley T. Falk, Luciano Mueller, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 1701-1733
Closed Access | Times Cited: 6
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Weisong Li, Kai Zhang, Wenjun Wang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Hongfu Liu, Dongdong Zhou, Dongqin Liu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 6
Antibody drug conjugates in the clinic
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 6
Open Access | Times Cited: 6
Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer
Sabrina Nucera, Chiara Conti, Federica Martorana, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1491-1491
Open Access | Times Cited: 6
Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy
Celia María Curieses Andrés, José Manuel Pérez de la Lastra, Elena Bustamante Munguira, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3123-3123
Open Access | Times Cited: 6
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
Yan Feng, Jaewon Lee, Liping Yang, et al.
Cell Reports (2023) Vol. 42, Iss. 12, pp. 113503-113503
Open Access | Times Cited: 14
Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections
Kenneth D. Johnson, James C. Delaney, Thomas Guillard, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 9, pp. e1011612-e1011612
Open Access | Times Cited: 11
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
Ye Hu, Fengxi Chen, Siwen Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells
Leila Pisheh, Serena Matis, Martina Taglieri, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1256-1256
Open Access | Times Cited: 4
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
Mayumi Sue, Takuya Tsubaki, Yoko Ishimoto, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0304985-e0304985
Open Access | Times Cited: 4
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases
Lu Wang, Yu‐Sheng Lin, Zhimeng Yao, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101118-101118
Open Access | Times Cited: 4
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 4
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
Yujun Tong, Xiaobing Fan, Huan Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Chenfei Zhou, Bin Wang, Christina T. Teng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models
Virginia Metrangolo, Mylan Blomquist, Ananya Dutta, et al.
Science Advances (2025) Vol. 11, Iss. 3
Open Access
A bioengineered antibody conjugate reshape dendritic cell viability for immune-tolerance modulation
Xiaohong Chen, Yalin Wang, Tao Xu, et al.
Chemical Engineering Journal (2025), pp. 160431-160431
Closed Access
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Jianli Zhao, Ziyue Zhou, Phei Er Saw, et al.
Journal of the National Cancer Center (2025)
Open Access
From Text to Insight: A Natural Language Processing-Based Analysis of Burst and Research Trends in HER2-low Breast Cancer Patients
Muyao Li, Ang Zheng, Mingjie Song, et al.
Ageing Research Reviews (2025) Vol. 106, pp. 102692-102692
Open Access
NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate
Elisa Chazeau, Angélique Pipier, K. David Wegner, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects
Zu-Chian Chiang, Shan Xu, Xiangqian Zhao, et al.
International Journal of Biological Macromolecules (2025), pp. 142844-142844
Closed Access
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access

Scroll to top